An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic Disorders
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs Mexiletine (Primary)
- Indications Myotonic dystrophy; Nondystrophic myotonia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Lupin
- 25 Nov 2024 Status changed from recruiting to completed.
- 03 May 2024 Planned End Date changed from 12 Mar 2024 to 8 Aug 2024.
- 03 May 2024 Planned primary completion date changed from 12 Mar 2024 to 24 Jun 2024.